Evidence Level:Sensitive: D – Preclinical
New
Title:
Protein kinase C targeting of luminal (T-47D), luminal/HER2-positive (BT474), and triple negative (HCC1806) breast cancer cells in-vitro with AEB071 (Sotrastaurin) is efficient but mediated by subtype specific molecular effects
Excerpt:Here were evaluated the AEB071 (Sotrastaurin™) treatment efficiency of breast cancer cell lines derived from estrogen receptor positive (T-47D), estrogen/HER2 receptor positive (BT474)... All breast cancer cell lines subjected to this study were sensitive to AEB071 treatment...A combined targeting of PKC and a subtype specific driver molecule might complement specified breast cancer treatment.
DOI:10.1007/s00404-022-06434-2